Source - LSE Regulatory
RNS Number : 5237N
ABCAM PLC
01 February 2021
 

For immediate release

01 February 2021

ABCAM PLC

("Abcam" or "Company")

Total Voting Rights - Voting Rights and Capital

 

In conformity with the Disclosure Rules and Transparency Rules, provision 5.6.1, the Company notifies the market of the following: 

The Company's issued share capital consists of 226,693,347 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury.

The above figure of 226,693,347 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

Date of Notification: 01 February 2021

For further information please contact:

Abcam

+ 44 (0) 1223 696 000

Marc Perkins, Company Secretary

 




Numis - Nominated Adviser & Joint Corporate Broker

+ 44 (0) 20 7260 1000

Garry Levin / Huw Jeremy


 

J.P.Morgan Cazenove - Joint Corporate Broker

James Mitford / Hemant Kapoor

 

 

       +44 (0) 20 7742 4000

 

Morgan Stanley - Joint Corporate Broker

Tom Perry / Luka Kezic

 

 

       +44 (0) 20 425 8000

 

FTI Consulting

Ben Atwell / Natalie Garland-Collins

 

 

       +44 (0) 20 3727 1000





Notes to Editors

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

 

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

 

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

 

Abcam's thirteen locations are in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

 

To find out more, please visit www.abcam.com and www.abcamplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRUPUQPPUPGUBG
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts